86 new risk factors identified in research co-led by USC Norris Comprehensive Cancer Center. San Francisco, CA (UroToday.com) — Some racial and ethnic groups suffer relatively more often, and fare worse, from common ailments compared to others. Prostate cancer is one disease where such health disparities occur: Risk for the disease is about 75% higher, […]
Prostate cancer is a highly heritable disease with large disparities in incidence rates across ancestry populations. We conducted a multiancestry meta-analysis of prostate cancer genome-wide association studies (107,247 cases and 127,006 controls) and identified 86 new genetic risk variants independently associated with prostate cancer risk, bringing the total to 269 known risk variants. The top […]
There is a growing interest to identify genetic factors contributing to the development of erectile dysfunction (ED). Since the early pedigree and twin studies suggested a genetic contribution to ED, a number of follow-up candidate gene studies have strengthened these associations. Candidate gene polymorphisms have been identified in endothelial nitric oxide synthase (eNOS), Angiotensin Converting […]
Nearly 70% of men between 60 and 69 years have benign prostatic hyperplasia (BPH). Prevalence and severity of lower urinary tract symptoms (LUTS) in men also increase with age and approaches 80% in men over 80 years. A significant percentage of these patients on medical management will require surgical management due to inadequate improvement in […]
− Expanded oncology portfolio includes comprehensive prostate cancer franchise to address patient management across the care continuum − – Agreement builds on Blue Earth Diagnostics’ established leadership position in rapid development and commercialization of PET radiopharmaceuticals – – Theranostic rhPSMA radiopharmaceuticals have potential utility in both diagnostic imaging and therapy of prostate cancer San Francisco, […]
$50,000 awards support the next generation of bladder cancer researchers San Francisco, CA (UroToday.com) — The Bladder Cancer Advocacy Network (BCAN) announced that it is accepting applications for our 2021 Young Investigator Awards (YIAs). These awards support the professional development of outstanding early-career research scientists and clinical cancer research investigators who have demonstrated a commitment […]
The role of non-tumour renal biopsy in predicting renal function after surgery for renal cell carcinoma (RCC) is poorly investigated. The aim of the study was to assess the impact of renal parenchymal histology on renal function after radical nephrectomy in a cohort of patients with RCC.
To evaluate the cost-effectiveness of percutaneous cryoablation (PCA) versus robot-assisted partial nephrectomy (RPN) in patients with small renal tumors (T1a stage), considering perioperative complications.
Metabolomics analysis possibly identifies new therapeutic targets in treatment resistance by measuring changes in metabolites accompanying cancer progression. We previously conducted a global metabolomics (G-Met) study of renal cell carcinoma (RCC) and identified metabolites that may be involved in sunitinib resistance in RCC.
format accepted as a poster presentation at the Southeastern Sectional Meeting of the American Urological Association in New Orleans, LA, on March 21, 2020INTRODUCTION: A proportion of prostate cancer (PCa) patients initially managed with active surveillance (AS) are upgraded to a higher Gleason score (GS) at the time of radical prostatectomy (RP).
